Results from clinical trials of a vaccine for the herpes simplex virus (HSV) has performed well in Phase 1 clinical trials.
|Head Researcher||Professor Ian Frazer|
|Body Part||Oral and genital skin|
|Process Used||Vaccine technology developed by Prof Frazer and Dr Jian Zhou|
|Commercial Partnerships||Amedus Vaccines|
Nineteen of the 20 people in the Phase 1 clinical trial of Professor Frazer’s new vaccine had produced T-cells in response against HSV-2 which causes genital herpes. Around one in six Australians carry the virus that causes itchy skin lesions, up to one in four Australians aged 40-49 have the virus. The vaccine relies on a novel set of enhancements to polynucleotide vaccine technology developed by Professor Frazer using observations made by him and by Dr Jian Zhou concerning the requirements for effective viral gene expression in human cells; and by Professor Frazer on the use of ubiquitin fusion proteins to enhance cellular immunity to viral proteins.
The clean safety profile and strong dose-dependent cellular immune responses observed, following intradermal injection of the HSV-2 vaccine in this study, were as expected with this vaccine technology. A Phase 2 study of vaccine efficacy for reduction of HSV viral shedding and symptomatic disease is underway.There is hope the vaccine will result in a “functional cure”, where the visible disease caused by the virus is reduced or prevented. The vaccine may subsequently be tested for its ability to prevent HSV infection.
Admedus will now move into a Phase 2 trial. Over time the trials will be extended to test whether the vaccine also works to prevent the spread of the virus but this type of study takes a long period and must involve lots of people.
Professor Ian Frazer